Skip to content

Association between anxiety and clinical outcomes in patients with hypertrophic cardiomyopathy

Association between anxiety and clinical outcomes in patients with hypertrophic cardiomyopathy

Status
Active, not recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000040759
Enrollment
Unknown
Registered
2020-12-09
Start date
2020-12-08
Completion date
Unknown
Last updated
2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertrophic cardiomyopathy

Interventions

Case series:None

Sponsors

Jiaxing Science and Technology Bureau
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: (1) The diagnostic criteria of hypertrophic cardiomyopathy are: cardiac color ultrasound suggests that the left ventricular wall is significantly thickened, especially the ventricular septal thickening is significant, ventricular septal thickening can be uniform hypertrophy, also can be uneven hypertrophy, asymmetric hypertrophy, obvious abrupt left ventricle, cardiac chamber stenosis.The endocardial fibrosis is thickened below the mitral and aortic valves; (3) Diagnostic criteria for anxiety disorders: consistent with the Chinese Anxiety Disorder Rating Scale; (4) Aged >=18 years; (5) Obtain the informed consent of the patient.

Exclusion criteria

Exclusion criteria: (1) Patients with advanced malignant tumors (2) Refuse to participate in the study

Design outcomes

Primary

MeasureTime frame
mortality;

Secondary

MeasureTime frame
HCM-related HF;

Countries

China

Contacts

Public ContactHe Chao-Jie

The First Hospital of Jiaxing

hechaojie824@163.com+86 18858370824

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026